Thermatrx sale to fund major initiatives for BSD
This article was originally published in Clinica
Executive Summary
Having fattened its wallet with the proceeds from the Thermatrx transaction, BSD Medical is now financially able to "aggressively pursue" the objectives of its corporate strategy. Salt Lake City-based BSD gained $40m from the sale of Thermatrx, a company specifically set up to commercialise BSD's microwave thermal treatment for benign prostate hyperplasia, to American Medical Systems (AMS) in July.